Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Identify passive funds with low turnover to improve tax efficiency and stability. Compare options and select high-quality, low-turnover strategies.
27,282 articlesBiotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Rivian shares jumped about 8% amid a crucial R2 production debut and rising software revenue, even as peers Tesla and...
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
AT&T and Verizon report Q1 2026 results as fiber deals reshape their paths. This analysis weighs dividends, cash flow...
Investors await the July 14 CPI release to gauge the path of inflation and interest rates. This guide breaks down wha...
A fresh U.S. government win could alter Palantir's growth trajectory and market perception. Here’s what investors sho...
The administration targets a $1.6 trillion tariff-revenue gap with a broader, slower path for tariffs that invites mo...
Bitcoin hovered near $80,000 as April payrolls undershot forecasts, renewing bets on Fed policy and a potential bitco...
A rival’s blowout earnings stirred optimism across hardware names. This piece breaks down why super micro computer st...
On June 22, the tape showed mixed signals: tech weakness dragged major indices lower, while staple names and other de...
A major reinsurance renewal helped Lemonade rewrite its profit picture, sending LMND higher in a short week. Here’s w...
When a pharma giant pays more than double a target’s value, the move sends shockwaves through investors. This article...